alkylating agent

Avastin for Glioblastomas: Where Do We Go After the Results of RTOG 0825?

July 22, 2013

We have tried almost everything to treat glioblastoma without much progress. For the last 10 years, the treatment for malignant glioma has remained the same: surgery, if possible, followed by radiation and temozolomide, an oral alkylating agent. Recently, bevacizumab (Avastin) has risen in prominence for the treatment of recurrent glioblastoma. A recent study, though, suggests it will not likely be adopted in initial treatments. [Read more]